Wilmington Savings Fund Society FSB Decreases Stock Position in Labcorp Holdings Inc. $LH

Wilmington Savings Fund Society FSB decreased its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 26.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 17,713 shares of the medical research company’s stock after selling 6,371 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Labcorp were worth $5,085,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in LH. Caldwell Trust Co acquired a new stake in shares of Labcorp during the second quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in shares of Labcorp in the third quarter worth about $28,000. Motco purchased a new position in Labcorp in the third quarter valued at about $32,000. Headlands Technologies LLC grew its stake in Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 96 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on LH. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. JPMorgan Chase & Co. upped their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Finally, Piper Sandler boosted their price objective on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $304.82.

Labcorp Trading Down 1.8%

Shares of LH stock opened at $265.71 on Thursday. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a market capitalization of $21.89 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 1.85 and a beta of 1.01. The stock has a fifty day moving average of $273.31 and a two-hundred day moving average of $269.71. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. The business had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, research analysts expect that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, February 27th. Labcorp’s dividend payout ratio is currently 27.53%.

Insider Activity at Labcorp

In other news, EVP Brian J. Caveney sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president owned 2,579 shares in the company, valued at approximately $734,782.89. This represents a 17.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 16,113 shares of company stock valued at $4,547,450. Insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.